Nestin

Candel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies

Retrieved on: 
Friday, October 1, 2021
Therapy, Glioblastoma, Clinical trial, Neoplasm, Pancreatic cancer, Herpes simplex virus, Society, Conference, Private Securities Litigation Reform Act, Immunogenic cell death, Cancer, Patient, MD, SEC, Adult, Form, GLOBE, Company, Immunotherapy, Large-cell lung carcinoma, CADL, CD8, Nestin, Trial of the century, Brain, Combination therapy, Nasdaq, Tumor microenvironment, HSV, ICP34.5, Pharmaceutical industry, Vaccine

At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment.

Key Points: 
  • At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment.
  • Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors.
  • Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021

Retrieved on: 
Thursday, September 9, 2021

At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment.

Key Points: 
  • At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment.
  • Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors.
  • Encouraging clinical results of the ongoing phase 1 clinical trial were recently presented at the 2021 American Society of Clinical Oncology Annual Meeting.
  • Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.

Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Nestin, Proteins, American Society of Clinical Oncology, Branches of biology, Medicine, Cancer, CAN-3110, Candel Therapeutics, CAN-3110, CANDEL THERAPEUTICS

The data are presented today in an Oral Abstract Session of the Clinical Science Symposium at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The data are presented today in an Oral Abstract Session of the Clinical Science Symposium at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • As of the data cutoff date of April 21, 2021:
    30 patients were evaluable for safety.
  • Based on these data, we are excited to advance this innovative agent into further clinical trials."
  • Nestin is highly expressed in glioma cells and other tumor tissue but is absent in the healthy adult brain.